Q3 FY2015 · ended Sep 30, 2015 · Revenue $0 · Filed Nov 19, 2015
VG Life Sciences Inc. (BIOM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2015, the quarter ended Sep 30, 2015, it reported revenue of $0 and a net loss of $1.0 million.
Revenue
$0
Net income
$-1.01M
+4.7% vs year-ago quarter
Operating cash flow
$-48,321
+96.8% vs year-ago quarter
Free cash flow
$-407,412
+72.9% vs prior quarter
EPS
—
Dividend per share
None
Shares outstanding
107.88M
+239.1% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIOM (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami, FL
- SEC filer status
- Smaller reporting company
- SEC CIK
- 1091326
- Former names
- SB Technology Holdings, Inc. (until May 4, 2026); VG Life Sciences Inc. (until Mar 6, 2026); VG Life Sciences, Inc. (until Oct 14, 2014); VIRAL GENETICS INC /DE/ (until Mar 25, 2009); 5 STARLIVING ONLINE INC (until Oct 18, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2015 Sep 30, 2015 |
Q2 FY2015 Jun 30, 2015 |
Q1 FY2015 Mar 31, 2015 |
Q4 FY2014 Dec 31, 2014 |
Q3 FY2014 Sep 30, 2014 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$644,446 | -$739,266 | -$801,480 | -$541,450 | -$798,772 |
| Net income | -$1.0M | -$1.4M | -$1.5M | -$424,500 | -$1.1M |
| Operating cash flow | -$48,321 | -$237,561 | -$165,042 | -$407,412 | -$1.5M |
| Free cash flow | — | — | — | -$407,412 | -$1.5M |
| Total assets | $1.1M | $1.1M | $1.2M | $1.3M | $1.1M |
| Stockholders' equity | -$4.3M | -$4.8M | -$4.7M | -$4.5M | -$5.2M |
| Cash and investments | $22,919 | $4,335 | $30,066 | $33,992 | $53,842 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Mar 30, 2016 | Mar 29, 2016 |
| 10-Q | Quarterly report | Nov 19, 2015 | Sep 30, 2015 |
| 10-Q | Quarterly report | Aug 19, 2015 | Jun 30, 2015 |
| 8-K |
Current report
Material agreement
|
May 21, 2015 | May 21, 2015 |
| 10-Q | Quarterly report | May 20, 2015 | Mar 31, 2015 |
| 8-K |
Current report
Agreement ended
|
May 18, 2015 | Mar 10, 2015 |
All 211 VG Life Sciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.